Immunic, Inc

Add to watchlist
€11.53
Last updated:06/15/2021
10VA: F
Immunic, Inc

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-re… Show more

P/E ratio
-

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-9.962M
-11.542M
-15.86%
-34.933M
-202.66%
-44.017M
-26.00%
Cashflow
Sum up money going in and out company
-9.664M
-9.738M
-0.77%
-28.545M
-193.13%
-46.124M
-61.58%
Total liabilities
All combined debts and obligations
10.34M
2.551M
-75.33%
7.592M
+197.61%
9.076M
+19.55%
Company profile
CEO
Dr. Daniel Vitt
Market capitalization
Micro (253.73M)